TrialSignal transduction and targeted therapy2025

A novel antituberculosis agent exhibits potent clinical efficacy and good safety profile: an open-label, randomized-controlled, multicenter, phase 2a trial.

Naihui Chu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.